Stipend and Dates

Up to $12,200. Broken up into multiple payments

Note: All dates and times are tentative. Cohort 3
Day -1 First Admit Aug 23, 2022 Tue
Day 8 Discharge Aug 31, 2022 Wed
Day 14 Second Admit Sep 06, 2022 Tue
Day 25 Discharge Sep 17, 2022 Sat
Follow-Up Visit Sep 22, 2022


Click here to make an appointment for ELL 22172-22172x Cohort 3

Or call 210-225-5437 for more information


Study Criteria

Females (non-childbearing)

Age:  18-65

BMI:  18.0 to 35.0 kg/m2    


Study Information

Indication: The investigational drug is being developed as a possible treatment for breast & endometrial cancer.

Route of Administration: Oral

Washout from previous study: Participation in a clinical study and received treatment within 30 days before dosing.

Females must not be able to have children (non-childbearing):

  • Documented hysterectomy (removal of uterus), bilateral salpingectomy (removal of both Fallopian tubes), bilateral tubal ligation, bilateral tubal occlusion, bilateral oophorectomy (removal of both ovaries)
  • Menopause more than one year prior to study entry (stopped having monthly menstrual periods more than one year ago) and confirmed at screening by a hormone test.

Study Reminders

  • 8 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment (including prescription, over the counter, herbal supplements and vitamins)
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a valid government issued identification card such as a driver's license, state issued ID card or passport.  You will be required to show this same photo ID at all study visits
  • Arrive 30 minutes before your appointment to complete paper work
ELL 22172-22172X Cohort 3
Healthy Non-Childbearing Females Only
Payment amount
Up to $12,200
18 - 65